Literature DB >> 36000051

Patients of stage I oral cancer with pathologically low-risk feature managed by primary tumor resection alone: Impact of depth of invasion and a nomogram analysis.

Ming-Hsien Tsai1,2,3, Hui-Shan Huang4, Hui-Ching Chuang1,2, Yu-Tsai Lin1,2,3, Kun-Lin Yang1,2, Hui Lu1, Chih-Yen Chien1,2,5.   

Abstract

Objectives: To evaluate the importance of depth of invasion (DOI) in patients with pathologically low-risk feature stage I oral squamous cell carcinoma (OSCC) managed by primary tumor resection alone.
Methods: Patients with stage I OSCC, at pathologically low risk, underwent primary tumor resection without neck dissection were enrolled retrospectively between 2007 and 2015. Low risk was defined as the absence of positive or close margins, lymphovascular invasion, perineural invasion, worst pattern of invasion-5, and poor differentiation in histologic grade. The primary endpoints included overall survival (OS), cancer specific survival (CSS), local recurrence free survival (LRFS), and regional recurrence free survival (RRFS). A nomogram based on the DOI was established for predicting RRFS.
Results: A total of 198 patients were enrolled in this study. DOI was the only prognosticator to achieve statistical significance in all primary endpoints according to univariate analysis. Patients with DOI <3 mm tumor showed better five-year OS, CSS, LRFS, and RRFS than those with DOI ≥3 mm tumor. The concordance index of the nomogram model without DOI was 0.684, which could increase to 0.733 when DOI was included in the calculation.
Conclusion: Patients with pathologically low-risk stage I OSCC correlate with a higher chance in occult neck metastasis if increasing DOI (≥3 mm) is noticed. Indeed, the chance of occult neck metastasis is significantly higher in this group (14% vs. 2%) than in those with DOI <3 mm. Elective neck dissection is advised if DOI is ≥3 mm to achieve better clinical outcomes. Level of Evidence: 4.
© 2022 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society.

Entities:  

Keywords:  depth of invasion; neck dissection; outcome; regional recurrence; stage I oral cancer

Year:  2022        PMID: 36000051      PMCID: PMC9392408          DOI: 10.1002/lio2.872

Source DB:  PubMed          Journal:  Laryngoscope Investig Otolaryngol        ISSN: 2378-8038


INTRODUCTION

Oral squamous cell carcinoma (OSCC) is an aggressive head and neck malignancy and also the fifth most common cancer in males in Taiwan. Early detection of OSCC is important but local or regional failure may appear in this cohort after treatment. Local invasion and neck lymph node metastasis are two common causes for treatment failure in OSCC. Because neck nodal metastasis has been shown to be one of the most significant prognostic factors of survival for patients with OSCC, elective neck dissection (END) has been strongly recommended to provide precise pathologic examination, better neck control rate, and survival. Generally, END will increase postoperative morbidity, including shoulder problems and pain; thus, it has a great impact on the quality of life in these patients. Some studies have described neck management with a watch‐and‐see strategy that could be equal in survival compared with END in selected patients with early stage OSCC. Studies have reported that adverse pathologic features, including grade of differentiation, perineural invasion (PNI), lymphovascular invasion (LVI), and worst pattern of invasion‐5 (WPOI‐5) are markers that increase the risk of locoregional recurrence in stage I/II OSCC. , , , In the eighth edition of the American Joint Committee on Cancer (AJCC), depth of invasion (DOI) has become a factor influencing T classification in OSCC. A DOI value >4 mm was shown to be associated with a higher rate of recurrence and worse outcomes in stage I/II OSCC. , , , However, only a few studies had focused on patients diagnosed with stage I OSCC. It was unclear whether neck dissection should be performed in patients with low‐risk stage I OSCC treated only with primary tumor resection. The aims of this study were to determine whether DOI can predict local or regional recurrence and impact survival in this cohort. In addition, we generated a prognostic nomogram that incorporated DOI and clinicopathological features to investigate whether DOI can be used to estimate the five‐year regional recurrence free survival (RRFS) rates in our cohort.

MATERIAL AND METHODS

Study population

In total, 198 consecutive patients with stage I OSCC (based on the eighth edition of the AJCC Staging), who underwent primary tumor resection alone with low‐risk pathological features at Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, were enrolled retrospectively between January 2007 and June 2015. Data were collected from the cancer database of Kaohsiung Chang Gung Memorial Hospital, Taiwan. Clinical N0 was defined as no palpable neck lymphadenopathy in a clinical examination and absence of enlarged lymph nodes on imaging study. All patients included in this study had clinical N0 disease preoperatively, with detailed clinical and pathological information available for review. Low‐risk tumor is defined as a pathologic feature without the presence of PNI, LVI, WPOI‐5, poorly differentiated squamous cell carcinoma, and neither close nor positive margins in surgical resection specimen. Patients who had (a) a history of any cancer, (b) prior treatment for head and neck cancer, (c) a positive lymph node, (d) nonsquamous cell carcinoma, and (e) received adjuvant treatment, such as radiotherapy alone or concurrent chemoradiotherapy, were excluded from this study. This yielded a homogenous patient population to evaluate DOI alone as the major prognostic factor in oncologic outcomes.

Statistical analysis

Statistical analyses were performed using SPSS 25.0 software (Armonk, NY: IBM Corp.). Outcomes of interest investigated included five‐year rates of overall survival (OS), cancer specific survival (CSS), local recurrence free survival (LRFS), and RRFS. OS was calculated as the interval from the date of radical surgery to the date of death due to any cause. CSS was calculated as the interval from the date of radical surgery to the date of death from oral cancer. LRFS referred to as the interval from the date of radical surgery to the date of local recurrence. RRFS was calculated as the interval from the date of radical surgery to the date of regional recurrence. The Kaplan–Meier method was used to estimate the probabilities of survival in each categorized factor. The log‐rank test account for each stratification factor was considered statistically significant using two‐tailed tests at p values less than .05. In addition, we created a prognostic nomogram that incorporated cancer location, histological grade, greatest size of tumor, and DOI by using the R software “rms” package (Version 5.1–0, Vanderbilt University, Nashville, TN, USA) with endpoints of five‐year RRFS rates. To ascertain the RRFS prediction accuracy of the nomogram, the concordance index (C‐index) was derived for the proposed nomogram models with and without the DOI; C‐index values of 0.5 and 1.0 were considered to signify random and perfect predictability, respectively. A calibration plot was used to determine whether the predicted survival rate was consistent with the actual observed survival rate. This study was approved by the Medical Ethics Committee and Human Clinical Trial Committee, Chang Gung Memorial Hospital (Ethical Application Reference number: 202100663B0).

RESULTS

A total of 198 patients were enrolled in this study. The clinical characteristics of patients are summarized in Table 1. The median age of patients was 53 years (range: 23–85). The study sample included 181 (91.4%) male and 17 (8.6%) female patients. Squamous cell carcinoma was the only histopathological cancer type in this population. The buccal mucosa (N = 80, 40.4%) was the most common tumor subsite, followed by the tongue (N = 79, 39.9%), lower lip (N = 13, 3.8%), lower gum (N = 10, 3.8%), mouth floor (N = 6, 3.8%), retromolar trigone (N = 4, 2.0%), hard palate (N = 4, 2.0%), upper lip (N = 1, 0.5%), and upper gum (N = 1, 0.5%). All the patients received primary tumor resection alone without END. No patient received adjuvant radiotherapy or concurrent chemoradiotherapy. The average greatest size of primary tumor was 9.5 mm (range: 1–20 mm). The average DOI was 2.6 mm (range: 1–5 mm)—105 (53%) and 93 (47%) patients had DOI values <3 mm and ≥3 mm, respectively. In this cohort, a cutoff of DOI = 3 mm was set for further analyses. Patients with DOI ≥3 mm in primary tumor had significantly higher rates of large tumor size and occurrence over buccal area (Table 2).
TABLE 1

Patient characteristics (n = 198)

CharacteristicsValue%
Median age (range), std, year53 (23, 85)11.4
Median follow‐up time (range), std, months79.3 (1.5, 156.1)39.3
SexMale18191.4
Female178.6
Smoking habitYes17085.9
No2814.1
Betel but habitYes13166.2
No6733.8
Alcohol drinking habitNo7236.4
Yes12663.6
Cancer locationTongue7939.9
Buccal8040.4
Other subsites3919.7
Histologic gradeWDSCC14472.7
MDSCC5427.3
Depth of invasion<3 mm10553.0
≥3 mm9347.0
Tumor greatest size≤10 mm11558.1
>10 mm8341.9
RecurrenceNo16784.3
Yes3115.7
Recurrent locationLocal1651.6
Regional1548.4

Abbreviations: MDSCC, moderately differentiated squamous cell carcinoma; WDSCC, well differentiated squamous cell carcinoma.

TABLE 2

Association between different depth of invasion and other clinical‐pathological factors

VariableDepth of invasion p value
<3 mm (N = 105)≧3 mm (N = 93)
Age<535146.9
≧535447
Smoking habitNo1810.198
Yes8783
Betel but habitNo4126.1
Yes6467
Alcohol drinking habitNo4230.258
Yes6363
Cancer locationTongue5029.032
Buccal3446
Other subsites2118
Histologic gradeWDSCC7668.907
MDSCC2925
Tumor greatest size≤10 mm7936<.001
>10 mm2657

Abbreviations: MDSCC, moderately differentiated squamous cell carcinoma; WDSCC, well differentiated squamous cell carcinoma.

Patient characteristics (n = 198) Abbreviations: MDSCC, moderately differentiated squamous cell carcinoma; WDSCC, well differentiated squamous cell carcinoma. Association between different depth of invasion and other clinical‐pathological factors Abbreviations: MDSCC, moderately differentiated squamous cell carcinoma; WDSCC, well differentiated squamous cell carcinoma. Patients were followed up for a median of 78.1 months in this cohort. Tumor recurrence occurred in 31 (15.7%) patients and included local recurrence (N = 16) and regional recurrence (N = 15). In a subgroup of patients with regional failure (N = 15), the nodal recurrence region was ipsilateral neck, and salvage neck dissection was performed in all. Extranodal extension pathologically was shown in 13 patients (86.7%) (Table 3).
TABLE 3

The characteristic of patients with regional recurrence (n = 15)

No.Tumor subsiteDOI (mm)Location of recurrenceSalvage treatmentStatus while last visit
1Tongue5Ipsilateral, I + II + IIISalvage neck dissection then CCRTDOD
2Tongue3Ipsilateral, I + II + IIISalvage neck dissection then CCRTDOD
3Tongue3Ipsilateral, IISalvage neck dissection then CCRTNED
4Buccal3Ipsilateral, ISalvage neck dissection aloneNED
5Buccal5Ipsilateral, I + IISalvage neck dissection then CCRTNED
6Buccal5Ipsilateral, I + II + IIISalvage neck dissection then CCRTNED
7Buccal5Ipsilateral, I + IISalvage neck dissection aloneNED
8Buccal4Ipsilateral, I + IISalvage neck dissection then CCRTDWOD
9Buccal4Ipsilateral, I + II + IIISalvage neck dissection then CCRTDOD
10Buccal1Ipsilateral, ISalvage neck dissection then CCRTDWOD
11Buccal2Ipsilateral, ISalvage neck dissection then CCRTNED
12Buccal4Ipsilateral, I + IISalvage neck dissection then CCRTDOD
13Buccal5Ipsilateral, ISalvage neck dissection then CCRTDOD
14Buccal5Ipsilateral, ISalvage neck dissection then CCRTDWOD
15Hard palate3Ipsilateral, ISalvage neck dissection then CCRTDOD

Abbreviations: DOI, depth of invasion; CCRT, concurrent chemoradiotherapy; DOD, died of disease; NED: no evidence of disease; DWOD, died without disease.

The characteristic of patients with regional recurrence (n = 15) Abbreviations: DOI, depth of invasion; CCRT, concurrent chemoradiotherapy; DOD, died of disease; NED: no evidence of disease; DWOD, died without disease. In a subgroup of patients with DOI ≥3 mm (N = 93), 13 (14.0%) had regional recurrence, whereas only 2 (2/105 = 2.0%) with DOI <3 mm had regional recurrence. Of the 13 patients with DOI ≥3 mm, who experienced regional recurrence, 10 had neck failure within the first year after primary treatment and 6 died of the disease. The five‐year OS, CSS, LRFS, and RRFS rates in this cohort were 88.6%, 94.2%, 91.4%, and 92.9%, respectively. We were interested in the effects of the clinicopathological factors, especially the role of DOI in the primary tumor. DOI itself might have an impact on survival. Five‐year survival rates of OS, CSS, LRFS, and RRFS were calculated for all factors and listed in Table 3. These results revealed that patients with DOI ≥3 mm over the tumor were significantly associated with lower rates of five‐year OS (p = .039), five‐year CSS (p = .011), five‐year LRFS (p = .016), and five‐year RRFS (p = .007) than those with DOI <3 mm. Survival curves of DOI strata for each outcome were drawn (Figure 1). Both cancer location over buccal mucosa and tumor size (>10 mm) were significant prognostic factors of poorer outcomes for the RRFS rate in the univariate analysis (Table 4). However, further multivariate analysis revealed that no factor had statistical significance in RRFS (DOI, p = .081; cancer location, p = .107; tumor size, p = .35).
FIGURE 1

Kaplan–Meier survival curves according to different depth of invasion. (A) Overall survival curves, (B) cancer‐specific survival curves, (C) local recurrence free survival curves, and (D) regional recurrence free survival curves

TABLE 4

Univariate analysis of factors impacting survival (n = 198)

Variable N 5 year OS (%) p 5 year CSS (%) p 5 year LRFS (%) p 5 year RRFS (%) p
Age (median)
< 539790.5.57995.7.59193.6.31491.7.396
≧5310186.993.989.194.0
Smoking habit
no2892.6.21692.6.8991.8.80992.9.904
yes17088.094.591.392.9
Betelnut chewing habit
no6789.5.91393.9.92290.5.80194.0.91
yes13188.194.292.092.3
Alcohol drinking habit
no7288.8.64494.2.70592.6.66193.0.77
yes12688.694.290.692.8
Cancer location
tongue7991.0.22594.9.7497.5.05296.2.022*
buccal8084.893.286.087.3
other subsites3991.594.188.897.4
Histologic grade
WDSCC14489.3.67694.9.55890.6.45794.4.221
MDSCC5487.092.593.288.8
Depth of invasion
<3 mm10592.2.039*98.1.011*95.8.016*97.1.007*
≥3 mm9384.489.886.288.0
Tumor greatest size
≤10 mm11589.3.86996.3.09893.7.2495.6.039*
>10 mm8387.791.388.189.0

*statistically significant p < 0.05.

Abbreviations: CSS, cancer specific survival; LRFS, local recurrence free survival; MDSCC, moderately differentiated squamous cell carcinoma; OS, overall survival; RRFS, regional recurrence free survival; WDSCC, well differentiated squamous cell carcinoma.

Kaplan–Meier survival curves according to different depth of invasion. (A) Overall survival curves, (B) cancer‐specific survival curves, (C) local recurrence free survival curves, and (D) regional recurrence free survival curves Univariate analysis of factors impacting survival (n = 198) *statistically significant p < 0.05. Abbreviations: CSS, cancer specific survival; LRFS, local recurrence free survival; MDSCC, moderately differentiated squamous cell carcinoma; OS, overall survival; RRFS, regional recurrence free survival; WDSCC, well differentiated squamous cell carcinoma. We analyzed the effect of DOI in primary buccal cancer (N = 80). The result showed that patients with buccal cancer and DOI ≥3 mm were significantly associated with lower rates of survival on five‐year CSS than those with DOI <3 mm (88.3% vs. 100%, p = .046). At other endpoints, patients with DOI ≥3 mm buccal cancer showed inferior survival than those in control groups of five‐year OS (80.1% vs. 91.2%, p = .239), LRFS (80.9% vs. 93%, p = .109), and RRFS (82.3% vs. 94%, p = .069), but these clinical outcomes did not achieve significance statistically (Table S1). A nomogram that incorporated with cancer location, histological grade, greatest size of tumor, and DOI was developed for predicting individualized five‐year RRFS rates in this cohort (Figure 2A). Another nomogram that incorporated with cancer location, histological grade, and tumor size was also implemented for comparison. The C‐index (95% CI) derived for the nomogram that incorporated with several clinicopathological features without DOI was 0.684 (0.545–0.823), whereas the C‐index (95% CI) derived for the nomogram model that incorporated with DOI and several clinicopathological features was 0.733 (0.615–0.851). These results indicate that the nomogram that incorporated with clinicopathological factors, including DOI, had a better performance in predicting the RRFS rate of patients with pathologically low risk, stage I oral cancer by primary tumor resection alone than the nomogram model with no DOI incorporated.
FIGURE 2

Nomogram and survival predictions. (A) Nomogram for predicted RRFS rate. A vertical line is drawn from each factor to the point score. By adding the points from all the factors, a total points score is reached, which is translated into five‐year RRFS rates by drawing a vertical line to its axis. (B) Calibration plots of the nomogram to predict five‐year RRFS rate. The diagonal line indicates ideal prediction, and the dark gray line indicates the predictive ability of our proposed nomogram. Gray dots with bars represent the performance and 95% CI of the nomogram when applied to the surviving cohorts. MDSCC, moderately differentiated squamous cell carcinoma; RRFS, regional recurrence free survival; WDSCC, well differentiated squamous cell carcinoma

Nomogram and survival predictions. (A) Nomogram for predicted RRFS rate. A vertical line is drawn from each factor to the point score. By adding the points from all the factors, a total points score is reached, which is translated into five‐year RRFS rates by drawing a vertical line to its axis. (B) Calibration plots of the nomogram to predict five‐year RRFS rate. The diagonal line indicates ideal prediction, and the dark gray line indicates the predictive ability of our proposed nomogram. Gray dots with bars represent the performance and 95% CI of the nomogram when applied to the surviving cohorts. MDSCC, moderately differentiated squamous cell carcinoma; RRFS, regional recurrence free survival; WDSCC, well differentiated squamous cell carcinoma

DISCUSSION

To our best knowledge, our study is the first large case study to evaluate the pathologically low‐risk stage I OSCC patients who were treated by primary tumor resection alone. The aim of this study is to identify that DOI could be a sole factor for recurrence and survival prediction in this unique low‐risk cancer population and provide information on their outcomes while there is no data exist to guide clinical decision making. Other high‐risk pathologic features would likely have a dominating effect in our statistical models, and were therefore excluded. In early stage (T1/T2) OSCC, DOI >4 mm had been shown to be associated with a worse outcome, and clinically, it was a strong predictor of occult metastatic neck disease. , , , Many studies have been published to discuss this issue although most of these studies had included both T1 and T2 OSCC. However, patients with cT1N0 and cT2N0 OSCCs have significantly different risks of local recurrence, neck lymph node metastasis, and different prognosis. , In oral cancer with stage of cT1N0, Low et al. noted that four or more adverse pathologic features and tumor thickness more than 5 mm signified an increased risk of locoregional failure. Tai et al. revealed that perineural invasion was associated with a higher rate of occult nodal metastasis and poor outcomes in 146 patients diagnosed with T1N0 OSCC. Zhang et al. studied a cohort of 65 patients with cT1N0 oral tongue cancer and found that tumors with DOI >3 mm were associated with higher occult neck metastasis rates. Our study demonstrated that the variable, DOI ≥3 mm is a negative prognosticator of five‐year OS, five‐year CSS, five‐year LRFS, and five‐year RRFS rates in patients with stage I oral cancer with low‐risk pathological feature. These findings further recognize the impact of DOI on locoregional recurrence and clinical outcomes. To date, no study has constructed a DOI‐based nomogram that predicts survival in this unique population. Our study established the multivariate nomogram that by integrating the clinicopathological variables, including location, histologic grade, tumor size, and DOI could yield a feasible result (c‐index: 0.733). The nomogram can provide more accurate prediction over five‐year RRFS rates in patients with pathologically low risk, stage I oral cancer managed through primary tumor resection alone than the nomogram model without DOI incorporated. It could help surgeons to identify patients at higher risk of regional failure. Based on our nomogram prediction, for a case with pathologically proven low‐risk stage I OSCC, who received primary tumor excision alone, with tumor location over tongue (score: 0), tumor size >10 mm (score: 53.72), moderately differentiated squamous cell carcinoma (score: 61.16), and DOI ≥3 mm (score: 100), the predicted five‐year RRFS rate would be 77.0%. However, under the same conditions, but with DOI <3 mm, which received a score of 0 instead of 100, the predicted five‐year RRFS rate would be 93.4%. Perhaps, END is advised if DOI is ≥3 mm in the image study or staged neck dissection is considered after primary tumor surgery. Sentinel lymph node biopsy (SLNB) may be another treatment opinion other than END strategy. Sentinel lymph nodes, the first nodes to drain cancer cells, are at highest risk for metastasis. In some cancers, such as melanoma and breast cancer, SLNB is widely used to identify whether lymph node metastasis is present. A negative SLNB result indicates that elective lymph node dissection is unnecessary, thereby sparing patients unnecessary surgery and avoiding surgical morbidity, while accurately upstaging malignancies. For oral cavity cancer, the concept of SLNB has evolved during the last decades. Many large single and multicenter studies, in which treatment of the neck was only performed after positive SLNs, have shown high sensitivities and negative predictive values. , , , Results from a meta‐analysis comprising 98 studies demonstrated the high specificity of SLNB and showed that SLNB is an accurate diagnostic tool that can be used in clinical practice to identify occult lymph node metastasis in early stage OSCC. There is an ongoing randomized phase II/III trial (NCT04333537)—SLNB versus END—for early oral cancer, with the collaboration of the American National Cancer Institute. The trial started on April 3, 2020, and planned to enroll 618 patients. The endpoints of this trial will compare both arms in patient‐reported neck and shoulder function, disease free survival, OS, local regional failure, distant metastasis, patient‐reported shoulder‐related quality of life, functional impairment and disability, general quality of life, nodal metastasis detection rate, pathologic false omission rate, and post‐surgery patient‐reported outcome. Hopefully, SLNB will become the solid evidence in the management of early oral cancer. Our study has some limitations. First, it is a retrospective study and all the patients underwent surgical procedures at a single institution by different head and neck surgeons. Thus, the study is prone to have a selection bias. Second, the issue of preoperative imaging study exists, which may lead to different judgments in neck management. Some patients underwent CT scans for evaluation, whereas others received MRI studies. Third, the study's results were not validated by using an independent dataset. External validation of the results by using an independent patient cohort can strengthen the derived evidence.

CONCLUSIONS

Our findings revealed that a tumor with DOI ≥3 mm was a negative prognostic factor in five‐year OS, CSS, LRFS, and RRFS rates among patients of oral cancer staged as pT1cN0 with low‐risk pathologically. An increasing DOI in patients of pT1cN0 with low risk in primary tumor should consider the need of neck dissection for regional control and better clinical outcomes.

AUTHOR CONTRIBUTIONS

Ming‐Hsien Tsai conceived and designed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft. Hui‐Shan Huang performed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft. Hui‐Ching Chuang, Yu‐Tsai Lin, and Kun‐Lin Yang performed the experiments, authored or reviewed drafts of the paper, approved the final draft. Hui Lu contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft. Chih‐Yen Chien conceived and designed the experiments, performed the experiments, analyzed the data, authored or reviewed drafts of the paper, approved the final draft.

FUNDING INFORMATION

This research received no specific grant from any funding agency in the public, commercial, or not‐for‐profit sectors.

CONFLICT OF INTEREST

The authors have no conflicts of interest to disclose. Table S1 Univariate Analysis of Factors Impacting Survival in primary buccal cancer (N = 80) Click here for additional data file.
  27 in total

Review 1.  Neck treatment and shoulder morbidity: still a challenge.

Authors:  Patrick J Bradley; Alfio Ferlito; Carl E Silver; Robert P Takes; Julia A Woolgar; Primož Strojan; Carlos Suárez; Hakan Coskun; Peter Zbären; Alessandra Rinaldo
Journal:  Head Neck       Date:  2010-10-19       Impact factor: 3.147

2.  Staging of early lymph node metastases with the sentinel lymph node technique and predictive factors in T1/T2 oral cavity cancer: A retrospective single-center study.

Authors:  Nicklas Juel Pedersen; David Hebbelstrup Jensen; Nora Hedbäck; Martin Frendø; Katalin Kiss; Giedrius Lelkaitis; Jann Mortensen; Anders Christensen; Lena Specht; Christian von Buchwald
Journal:  Head Neck       Date:  2015-09-02       Impact factor: 3.147

3.  Topographical distribution of sentinel nodes and metastases from T1-T2 oral squamous cell carcinomas.

Authors:  Jacob Mølstrøm; Mark Grønne; Anders Green; Vivi Bakholdt; Jens Ahm Sørensen
Journal:  Eur J Cancer       Date:  2018-12-12       Impact factor: 9.162

4.  Occult metastases detected by sentinel node biopsy in patients with early oral and oropharyngeal squamous cell carcinomas: impact on survival.

Authors:  Martina A Broglie; Stephan K Haerle; Gerhard F Huber; Sarah R Haile; Sandro J Stoeckli
Journal:  Head Neck       Date:  2012-05-18       Impact factor: 3.147

5.  Validation of the risk model: high-risk classification and tumor pattern of invasion predict outcome for patients with low-stage oral cavity squamous cell carcinoma.

Authors:  Yufeng Li; Shuting Bai; William Carroll; Dan Dayan; Joseph C Dort; Keith Heller; George Jour; Harold Lau; Carla Penner; Michael Prystowsky; Eben Rosenthal; Nicolas F Schlecht; Richard V Smith; Mark Urken; Marilena Vered; Beverly Wang; Bruce Wenig; Abdissa Negassa; Margaret Brandwein-Gensler
Journal:  Head Neck Pathol       Date:  2012-12-19

6.  Factors predicting poor outcomes in T1N0 oral squamous cell carcinoma: indicators for treatment intensification.

Authors:  Tsu-Hui Hubert Low; Kan Gao; Ruta Gupta; Anthony Clifford; Michael Elliott; Sydney Ch'ng; Chris Milross; Jonathan R Clark
Journal:  ANZ J Surg       Date:  2016-03-17       Impact factor: 1.872

7.  Sentinel lymph node biopsy as an alternative to wait and see policy in patients with small T1 oral cavity squamous cell carcinoma.

Authors:  Harri Keski-Säntti; Risto Kontio; Ilmo Leivo; Jyrki Törnwall; Sorjo Mätzke; Antti A Mäkitie; Timo Atula
Journal:  Acta Otolaryngol       Date:  2008-01       Impact factor: 1.494

8.  Elective Neck Dissection or Sentinel Lymph Node Biopsy in Early Stage Oral Cavity Cancer Patients: The Dutch Experience.

Authors:  Inne J den Toom; Koos Boeve; Daphne Lobeek; Elisabeth Bloemena; Maarten L Donswijk; Bart de Keizer; W Martin C Klop; C René Leemans; Stefan M Willems; Robert P Takes; Max J H Witjes; Remco de Bree
Journal:  Cancers (Basel)       Date:  2020-07-03       Impact factor: 6.639

9.  Sentinel lymph-node biopsy in head and neck cancer.

Authors:  S Höft; S Maune; C Muhle; W Brenner; N Czech; W-U Kampen; U Jänig; M Laudien; S Gottschlich; P Ambrosch
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

10.  Depth of invasion, tumor budding, and worst pattern of invasion: prognostic indicators in early-stage oral tongue cancer.

Authors:  Alhadi Almangush; Ibrahim O Bello; Harri Keski-Säntti; Laura K Mäkinen; Joonas H Kauppila; Matti Pukkila; Jaana Hagström; Jussi Laranne; Satu Tommola; Outi Nieminen; Ylermi Soini; Veli-Matti Kosma; Petri Koivunen; Reidar Grénman; Ilmo Leivo; Tuula Salo
Journal:  Head Neck       Date:  2013-09-02       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.